Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Alzinova

OM:ALZ
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALZ
OM
SEK78M
Market Cap
  1. Home
  2. SE
  3. Pharmaceuticals & Biotech
Company description

Alzinova AB, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of Alzheimer’s disease in Sweden. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Alzinova has significant price volatility in the past 3 months.
ALZ Share Price and Events
7 Day Returns
26.3%
OM:ALZ
4.1%
SE Biotechs
-1.6%
SE Market
1 Year Returns
-32.5%
OM:ALZ
-29.7%
SE Biotechs
-12.2%
SE Market
ALZ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alzinova (ALZ) 26.3% 7.1% -21.2% -32.5% -31.9% -
SE Biotechs 4.1% -5.7% -8.7% -29.7% 3.4% 33.3%
SE Market -1.6% -18.7% -22.6% -12.2% -13.9% -15.5%
1 Year Return vs Industry and Market
  • ALZ underperformed the Biotechs industry which returned -29.7% over the past year.
  • ALZ underperformed the Market in Sweden which returned -12.2% over the past year.
Price Volatility
ALZ
Industry
5yr Volatility vs Market

ALZ Value

 Is Alzinova undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Alzinova. This is due to cash flow or dividend data being unavailable. The share price is SEK10.56.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alzinova's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alzinova's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OM:ALZ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK-0.81
OM:ALZ Share Price ** OM (2020-04-03) in SEK SEK10.56
Sweden Biotechs Industry PE Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 40.26x
Sweden Market PE Ratio Median Figure of 356 Publicly-Listed Companies 14.34x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alzinova.

OM:ALZ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:ALZ Share Price ÷ EPS (both in SEK)

= 10.56 ÷ -0.81

-13.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alzinova is loss making, we can't compare its value to the SE Biotechs industry average.
  • Alzinova is loss making, we can't compare the value of its earnings to the Sweden market.
Price based on expected Growth
Does Alzinova's expected growth come at a high price?
Raw Data
OM:ALZ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Sweden Biotechs Industry PEG Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 1.37x
Sweden Market PEG Ratio Median Figure of 233 Publicly-Listed Companies 0.98x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alzinova, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alzinova's assets?
Raw Data
OM:ALZ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK7.74
OM:ALZ Share Price * OM (2020-04-03) in SEK SEK10.56
Sweden Biotechs Industry PB Ratio Median Figure of 54 Publicly-Listed Biotechs Companies 3.17x
Sweden Market PB Ratio Median Figure of 772 Publicly-Listed Companies 2.11x
OM:ALZ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:ALZ Share Price ÷ Book Value per Share (both in SEK)

= 10.56 ÷ 7.74

1.36x

* Primary Listing of Alzinova.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alzinova is good value based on assets compared to the SE Biotechs industry average.
X
Value checks
We assess Alzinova's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alzinova has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ALZ Future Performance

 How is Alzinova expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alzinova has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alzinova expected to grow at an attractive rate?
  • Unable to compare Alzinova's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Alzinova's earnings growth to the Sweden market average as no estimate data is available.
  • Unable to compare Alzinova's revenue growth to the Sweden market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OM:ALZ Future Growth Rates Data Sources
Data Point Source Value (per year)
Sweden Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 16%
Sweden Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 9.2%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 8%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OM:ALZ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OM:ALZ Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
OM:ALZ Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 7 -3 -6
2019-09-30 5 -6 -5
2019-06-30 6 -5 -5
2019-03-31 8 -3 -5
2018-12-31 9 -4 -4
2018-09-30 11 -2 -3
2018-06-30 10 -2 -3
2018-03-31 8 -2 -2
2017-12-31 6 -2 -3
2017-09-30 5 -2 -3
2017-06-30 4 -3 -3
2017-03-31 5 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Alzinova is high growth as no earnings estimate data is available.
  • Unable to determine if Alzinova is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OM:ALZ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Alzinova Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:ALZ Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
OM:ALZ Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 -0.81
2019-09-30 -0.60
2019-06-30 -0.62
2019-03-31 -0.56
2018-12-31 -0.56
2018-09-30 -0.55
2018-06-30 -0.49
2018-03-31 -0.46
2017-12-31 -0.46
2017-09-30 -0.48
2017-06-30 -0.56
2017-03-31 -0.65

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Alzinova will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Alzinova's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Alzinova's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Alzinova's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Alzinova's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alzinova has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ALZ Past Performance

  How has Alzinova performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alzinova's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alzinova does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Alzinova's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alzinova's 1-year growth to the SE Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Alzinova's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alzinova Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:ALZ Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 6.81 -6.19 12.99
2019-09-30 4.90 -5.48 10.45
2019-06-30 6.33 -5.33 11.66
2019-03-31 8.01 -4.50 12.58
2018-12-31 9.36 -4.19 13.55
2018-09-30 11.04 -3.00 13.95
2018-06-30 9.99 -2.68 12.65
2018-03-31 8.36 -2.48 10.77
2017-12-31 5.79 -2.51 8.28
2017-09-30 5.09 -3.02 8.10
2017-06-30 4.45 -3.42 7.87
2017-03-31 4.63 -3.56 8.20
2016-12-31 5.25 -2.96 8.22
2016-09-30 4.70 -3.66 8.36
2016-06-30 3.84 -3.65 7.49
2016-03-31 2.34 -3.42 5.76
2015-12-31 1.00 -3.41 4.40
2014-12-31 0.95 -0.47 0.69
2013-12-31 0.84 -0.34 0.58

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alzinova has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alzinova has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alzinova improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alzinova's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alzinova has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ALZ Health

 How is Alzinova's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alzinova's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alzinova is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alzinova's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alzinova's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 42.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alzinova Company Filings, last reported 3 months ago.

OM:ALZ Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 59.11 0.80 33.73
2019-09-30 61.96 0.80 36.72
2019-06-30 62.56 0.80 39.13
2019-03-31 62.58 0.80 40.65
2018-12-31 63.75 0.80 42.35
2018-09-30 27.33 0.80 8.60
2018-06-30 27.79 0.80 11.01
2018-03-31 28.54 0.80 14.18
2017-12-31 29.39 0.80 17.88
2017-09-30 30.33 0.80 21.36
2017-06-30 30.47 0.80 22.38
2017-03-31 31.02 0.80 23.66
2016-12-31 31.90 0.80 25.04
2016-09-30 19.13 0.80 13.85
2016-06-30 19.66 0.80 15.19
2016-03-31 20.35 0.80 17.40
2015-12-31 20.63 0.77 18.50
2014-12-31 1.55 0.40 0.26
2013-12-31 0.72 0.40 0.08
  • Alzinova's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (25% vs 1.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Alzinova has sufficient cash runway for more than 3 years based on current free cash flow.
  • Alzinova has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 22.7% each year.
X
Financial health checks
We assess Alzinova's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alzinova has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ALZ Dividends

 What is Alzinova's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alzinova dividends.
If you bought SEK2,000 of Alzinova shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alzinova's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alzinova's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OM:ALZ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 231 Stocks 3.9%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1%
Sweden Bottom 25% Dividend Yield 25th Percentile 2%
Sweden Top 25% Dividend Yield 75th Percentile 6.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OM:ALZ Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alzinova has not reported any payouts.
  • Unable to verify if Alzinova's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alzinova's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alzinova has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Alzinova's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alzinova afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alzinova has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ALZ Management

 What is the CEO of Alzinova's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kristina Torfgård
TENURE AS CEO 1.3 years
CEO Bio

Dr. Kristina Torfgård Ph.D. serves as CEO at Alzinova AB since 2019. She serves as Vice President & Global Project Head at Albireo AB. Dr. Torfgård served as Vice President of Clinical & Regulatory Affairs of Albireo AB since February 2015 until February 2016. Dr. Torfgård has experience in drug development covering the full product lifecycle from pre-clinical evaluation, through clinical development, launch and life cycle management in pharmaceutical and biotech industry. Her experience covers multiple therapeutic and disease areas eg gastrointestinal, neuroscience, cardiovascular and metabolic disease/diabetes. At AstraZeneca, she worked several years in the clinical organization, held different senior and global leadership roles. Dr. Torfgård holds a MSc in Pharmacy and a PhD in Clinical Pharmacology. She studied PhD in Medical Science, Clinical Pharmacology at Linköping University from 1988 to 1992. She studied MSc Pharmacy at Uppsala University from 1984 to 1992.

CEO Compensation
  • Insufficient data for Kristina to compare compensation growth.
  • Insufficient data for Kristina to establish whether their remuneration is reasonable compared to companies of similar size in Sweden.
Management Team Tenure

Average tenure of the Alzinova management team in years:

1.3
Average Tenure
  • The average tenure for the Alzinova management team is less than 2 years, this suggests a new team.
Management Team

Kristina Torfgård

TITLE
Chief Executive Officer
TENURE
1.3 yrs

Anders Sandberg

TITLE
Co-Founder & Chief Scientific Officer
AGE
47

Håkan Skogström

TITLE
Chief Financial Officer
AGE
58
TENURE
0.1 yrs

Anders Bylock

TITLE
Chief Medical Officer
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Alzinova board of directors in years:

1.3
Average Tenure
54
Average Age
  • The average tenure for the Alzinova board of directors is less than 3 years, this suggests a new board.
Board of Directors

Björn Larsson

TITLE
Chairman
AGE
54

Anders Sandberg

TITLE
Co-Founder & Chief Scientific Officer
AGE
47

Clas Malmeström

TITLE
Director
AGE
54

Anders Waas

TITLE
Director
AGE
62
TENURE
1.3 yrs

Carol Routledge

TITLE
Director
TENURE
1.3 yrs

Pernilla Sandwall

TITLE
Director
AGE
56
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
04. Dec 19 Sell Per Wester Individual 02. Dec 19 02. Dec 19 -10,000 SEK15.10 SEK-151,000
X
Management checks
We assess Alzinova's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alzinova has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ALZ News

Simply Wall St News

Are Insiders Buying Alzinova AB (STO:ALZ) Stock?

For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' Check out our latest analysis for Alzinova The Last 12 Months Of Insider Transactions At Alzinova In the last twelve months, the biggest single purchase by an insider was when Chief Executive Officer Per Wester bought kr571k worth of shares at a price of kr14.94 per share. … It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. … OM:ALZ Recent Insider Trading, July 25th 2019 Insider Ownership of Alzinova I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders.

Simply Wall St -

Do Insiders Own Lots Of Shares In Alzinova AB (STO:ALZ)?

Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. … See our latest analysis for Alzinova OM:ALZ Ownership Summary, July 4th 2019 What Does The Institutional Ownership Tell Us About Alzinova? … General Public Ownership The general public -- mostly retail investors -- own 65% of Alzinova.

Simply Wall St -

Some Alzinova (STO:ALZ) Shareholders Are Down 23%

So the share price itself impacts the value of the shares (as it determines the cost of capital). … The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. … We note that Alzinova's TSR, at -20% is higher than its share price return of -23%.

Simply Wall St -

Have Insiders Been Buying Alzinova AB (STO:ALZ) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Alzinova AB (STO:ALZ). … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Alzinova Insider Transactions Over The Last Year.

Simply Wall St -

What Kind Of Shareholder Owns Most Alzinova AB (STO:ALZ) Stock?

Every investor in Alzinova AB (STO:ALZ) should be aware of the most powerful shareholder groups. … I quite like to see at least a little bit of insider ownership. … With a market capitalization of kr203m, Alzinova is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

ALZ Company Info

Description

Alzinova AB, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of Alzheimer’s disease in Sweden. It focuses on developing ALZ-101, an oligomer-directed vaccine; and ALZ-201, a monoclonal antibody that is used for the treatment of oligomeric Aß. The company was founded in 2011 and is based in Gothenburg, Sweden.

Details
Name: Alzinova AB
ALZ
Exchange: OM
Founded: 2011
SEK77,555,496
7,633,415
Website: http://www.alzinova.com
Address: Alzinova AB
Erik Dahlbergsgatan 11A,
Gothenburg,
Västra Götaland County, 411 26,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM ALZ Share Capital OMX Nordic Exchange Stockholm SE SEK 25. Nov 2015
Number of employees
Current staff
Staff numbers
0
Alzinova employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 22:22
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.